The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial.
Li-Tzong Chen
No relevant relationships to disclose
Jen-Shi Chen
No relevant relationships to disclose
Yee Chao
No relevant relationships to disclose
Chang-Sung Tsai
No relevant relationships to disclose
Yan-Shen Shan
No relevant relationships to disclose
Chiun Hsu
No relevant relationships to disclose
Shiu-Feng Huang
No relevant relationships to disclose
Hsiao-Hui Tsou
No relevant relationships to disclose
Kuan-Der Lee
No relevant relationships to disclose
Chang-Fang Chiu
No relevant relationships to disclose
Kun-Ming Rau
No relevant relationships to disclose
Ching-Liang Ho
No relevant relationships to disclose
Ming-Sun Yu
No relevant relationships to disclose